| Title |
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity A Phase I Trial
|
|---|---|
| Published in |
JACC: CardioOncology, July 2019
|
| DOI | 10.1016/j.jaccao.2019.06.004 |
| Pubmed ID | |
| Authors |
Darryl P. Leong, Tammy Cosman, Muhammad M. Alhussein, Nidhi Kumar Tyagi, Sarah Karampatos, Carly C. Barron, Douglas Wright, Vikas Tandon, Patrick Magloire, Philip Joseph, David Conen, P.J. Devereaux, Peter M. Ellis, Som D. Mukherjee, Sukhbinder Dhesy-Thind |
X Demographics
The data shown below were collected from the profiles of 54 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 17 | 31% |
| Canada | 5 | 9% |
| Spain | 3 | 6% |
| Japan | 3 | 6% |
| Belgium | 1 | 2% |
| Indonesia | 1 | 2% |
| Djibouti | 1 | 2% |
| Brazil | 1 | 2% |
| Egypt | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 20 | 37% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 36 | 67% |
| Practitioners (doctors, other healthcare professionals) | 8 | 15% |
| Scientists | 7 | 13% |
| Science communicators (journalists, bloggers, editors) | 3 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 68 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 11 | 16% |
| Researcher | 9 | 13% |
| Student > Bachelor | 6 | 9% |
| Student > Ph. D. Student | 4 | 6% |
| Student > Master | 4 | 6% |
| Other | 13 | 19% |
| Unknown | 21 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 50% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Immunology and Microbiology | 2 | 3% |
| Agricultural and Biological Sciences | 1 | 1% |
| Economics, Econometrics and Finance | 1 | 1% |
| Other | 3 | 4% |
| Unknown | 23 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2021.
All research outputs
#1,235,862
of 25,789,020 outputs
Outputs from JACC: CardioOncology
#111
of 477 outputs
Outputs of similar age
#25,223
of 344,872 outputs
Outputs of similar age from JACC: CardioOncology
#1
of 5 outputs
Altmetric has tracked 25,789,020 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 477 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 28.2. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,872 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them